Brenda Chyla

11.6k total citations · 5 hit papers
84 papers, 4.8k citations indexed

About

Brenda Chyla is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Brenda Chyla has authored 84 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Genetics, 43 papers in Hematology and 26 papers in Molecular Biology. Recurrent topics in Brenda Chyla's work include Chronic Lymphocytic Leukemia Research (42 papers), Acute Myeloid Leukemia Research (39 papers) and Lymphoma Diagnosis and Treatment (20 papers). Brenda Chyla is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Acute Myeloid Leukemia Research (39 papers) and Lymphoma Diagnosis and Treatment (20 papers). Brenda Chyla collaborates with scholars based in United States, Australia and Germany. Brenda Chyla's co-authors include Jalaja Potluri, Andrew H. Wei, Courtney D. DiNardo, Keith W. Pratz, Brian A. Jonas, Tu Xu, Daniel A. Pollyea, Marina Konopleva, Anthony Letai and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Blood.

In The Last Decade

Brenda Chyla

82 papers receiving 4.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology profile →
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Peers

Countries citing papers authored by Brenda Chyla

Since Specialization

Citations

This map shows the geographic impact of Brenda Chyla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Chyla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Chyla more than expected).

Fields of papers citing papers by Brenda Chyla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda Chyla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Chyla. The network helps show where Brenda Chyla may publish in the future.

Co-authorship network of co-authors of Brenda Chyla

This figure shows the co-authorship network connecting the top 25 collaborators of Brenda Chyla. A scholar is included among the top collaborators of Brenda Chyla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda Chyla. Brenda Chyla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab 2024 ·HemaSphere ·Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour	1
2	Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes 2024 ·Blood ·Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, (unknown), Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Péterlin, Brenda Chyla, (unknown), Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia‐Manero	7
3	A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia 2023 ·Hematological Oncology ·Brian A. Jonas, Jing‐Zhou Hou, Gail J. Roboz, Caroline Alvares, Deepa Jeyakumar, John Edwards, Harry P. Erba, Richard Kelly, Christoph Röllig, Walter Fiedler, Deanna J. Brackman, (unknown), Brenda Chyla, (unknown), Justin M. Watts	12
4	MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) 2023 ·Hematological Oncology ·Arnon P. Kater, Rosemary Harrup, Thomas J. Kipps, Barbara Eichhorst, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani‐Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F. Seymour	8
5	AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza) 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Marina Konopleva, Courtney D. DiNardo, Yan Sun, Sanam Loghavi, Paul Jung, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea	2
6	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia breakdown → 2022 ·Journal of Clinical Oncology ·Naval Daver, Alexander E. Perl, Joseph Maly, Mark J. Levis, Ellen K. Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramón V. Tiu, Kiran Naqvi, Monique Dail, Deanna J. Brackman, (unknown), Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman	123
7	Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia 2022 ·Clinical Cancer Research ·Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei	59
8	Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine 2022 ·Clinical Cancer Research ·Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo	75
9	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia 2021 ·Blood ·Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, (unknown), (unknown), Brenda Chyla, Kavita Sail, John C. Pesko, Madhavi Pai, (unknown), Michael Hallek, Jennifer R. Brown, Othman Al‐Sawaf	8
10	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations 2020 ·Blood ·Daniel A. Pollyea, Courtney D. DiNardo, Martha Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, Benjamin D. Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, (unknown), Hagop M. Kantarjian	27
11	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study breakdown → 2019 ·Journal of Clinical Oncology ·Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, (unknown), John Hayslip, Gail J. Roboz	456
12	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study breakdown → 2018 ·The Lancet Oncology ·Courtney D. DiNardo, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Michael J. Thirman, Martha Arellano, Mark G. Frattini, Hagop M. Kantarjian, Relja Popovic, Brenda Chyla, Tu Xu, Martin Dunbar, Suresh Agarwal, Rod Humerickhouse, Mack Mabry, Jalaja Potluri, Marina Konopleva, Daniel A. Pollyea	498
13	Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies 2017 ·Blood ·Sathej Gopalakrishnan, Brenda Chyla, Sven Mensing, Rajeev Menon, Rod Humerickhouse, Walid M. Awni, Ahmed Hamed Salem, Kevin J. Freise	2
14	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma 2015 ·Annals of Oncology ·Mark R. Middleton, Philip Friedlander, Omid Hamid, Adil Daud, Ruth Plummer, Nancy Falotico, Brenda Chyla, Fang Jiang, Evelyn McKeegan, Nael M. Mostafa, Zhu Ming, Jiang Qian, Mark D. McKee, Yan Luo, Vincent L. Giranda, Grant A. McArthur	69
15	A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) 2014 ·Blood ·Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda Chyla, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel Johansson, Rod Humerickhouse, Mack Mabry, Richard M. Stone, Hagop M. Kantarjian, Anthony Letai	50
16	Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target 2013 ·Leukemia ·Jason G. Harb, Paolo Neviani, Brenda Chyla, Justin J. Ellis, Gregory Ferenchak, Joshua J. Oaks, Christopher J. Walker, Peter Hokland, Denis‐Claude Roy, M. A. Caligiuri, Guido Marcucci, Claudia S. Huettner, Danilo Perrotti	15
17	A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report. 2013 ·Journal of Clinical Oncology ·Jack M. Su, Patrick A. Thompson, (unknown), Xiao‐Nan Li, Lindsay Kilburn, Arzu Onar‐Thomas, Mehmet Koçak, Brenda Chyla, Evelyn McKeegan, Katherine E. Warren, Stewart Goldman, Ian F. Pollack, Maryam Fouladi, Alice P. Chen, Malcolm A. Smith, Vincent L. Giranda, James M. Boyett, Susan M. Blaney, Larry E. Kun	3
18	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study 2012 ·Blood ·John F. Seymour, Matthew S. Davids, Mary Ann Anderson, Thomas J. Kipps, William G. Wierda, John M. Pagel, Brad S. Kahl, Thomas P. Miller, (unknown), Cathy E. Nolan, Lori A. Gressick, Hao Xiong, David C.S. Huang, Brenda Chyla, Todd Busman, Alison M. Graham, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew W. Roberts	6
19	Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks 2008 ·The EMBO Journal ·Sarah K. Knutson, Brenda Chyla, Joseph M. Amann, Srividya Bhaskara, Stacey S. Huppert, Scott W. Hiebert	216
20	Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control 2008 ·Molecular Cell ·Srividya Bhaskara, Brenda Chyla, Joseph M. Amann, Sarah K. Knutson, David Cortez, Zu-Wen Sun, Scott W. Hiebert	291

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact